On 23 September 2024, ten23 health celebrated the inauguration of its VIVA2® facility in Visp, in the vicinity of our BioArk Visp technology site, bringing to fruition an ambitious project announced in June 2022. This new state-of-the-art infrastructure considerably strengthens the region’s production capacity for sterile medicines.
The inauguration of the VIVA2® facility by ten23 health in Visp represents a major step forward for the pharmaceutical industry in Valais, combining technological innovation and sustainability. This new infrastructure is designed to meet the growing challenges of the sector, while strengthening the region’s position as a centre of excellence in life sciences.
A state-of-the-art facility
VIVA2® stands out for its cutting-edge technological features:
- A high-performance aseptic filling system with 8 filling heads
- A design that complies with the latest Annex 1 requirements, guaranteeing the highest standards of quality and safety
- Impressive production capacity, exceeding 30 million units per year
- Remarkable versatility, enabling the filling of a variety of containers: syringes, cartridges and vials of different sizes
- Advanced technologies, including headspace-free filling for optimum accuracy
- A sophisticated process control system, ensuring constant and rigorous production monitoring
These features make the VIVA2® particularly well-suited to the manufacture of complex sterile pharmaceutical products, offering exceptional flexibility and precision.
A commitment to sustainability
VIVA2® also embodies ten23 health’s commitment to sustainability. The façade of the building is fitted with photovoltaic panels, which generate a significant proportion of the energy needed to run the plant. This eco-responsible approach is part of the company’s long-term vision.
A major asset for the Valais and life sciences
The inauguration of VIVA2® represents a decisive turning point for the pharmaceutical industry in Valais. It strengthens the region’s position as a centre of innovation in the life sciences, potentially attracting new investment and talent.
It testifies to the dynamism of the local biopharmaceutical sector and opens up new prospects for the research, development and production of innovative medicines in the region.
This achievement positions the Valais as a key player on the international life sciences scene.